anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: To obtain a cosmetic, containing a solvent extract separated from a seed of Cuminum cyminum L., safe in application to the skin capable of inhibiting tyrosinase activities and excellent in beautifying and whitening actions on the skin. CONSTITUTION: This cosmetic contains a solvent extract separated from a seed of Cuminum cyminum L. with water or a hydrophilic organic solvent (e.g. ethanol, methanol or acetone), preferably water or ethanol or a mixed solvent thereof. The extract separated from the Cuminum cyminum L. is obtained by adding, e.g. 300ml 50% ethanol to 10g seed (dried product) of the Cuminum cyminum L., allowing the resultant mixture to stand for 5 days while occasionally stirring the mixture, filtering the extract, evaporating the prepared filtrate and then freeze-drying the evaporated filtrate. Other cosmetic raw materials, etc., can then be added to the obtained extract to afford a lotion, a cream, etc.
Individuals with language difficulties (e.g., vocabulary or forming sentences) can find it difficult to communicate and express their thoughts. Speech-language therapists sometimes encourage individuals with language difficulties to use hand gestures. By using gestures these individuals may find it easier to express their thoughts and their communication partners may find it easier to comprehend them. The researchers aim to answer the question: which skills are needed to produce highly comprehensible gestures? The answers to this question can inspire future language therapy for individuals with language difficulties.

Task1. Participants sees 30 items from the Boston Naming Task one by one. The researcher explains that she can not see the screen. When an image appears, the examiner asks the participant to describe the item without speaking, but by using hand gestures. These gesture versions are recorded on video. The researcher indicates which gesture strategy the participant used with each executed gesture (i.e., sketch, shape, object, or deictic). In addition, 200 adults with a typical development assess the intelligibility of each gesture. The recordings are presented one by one in a random order. The evaluators must write down what concept the person depicts on the video. By adding the correct responses per participant, each participant receives a skill score. This skill score is related to the individual results of cognitive testing.

Task2. Participants watch a cartoon. They tell the story to the researcher who "has never seen the cartoon and does not know what is happening". Participants do not receive instructions on the use of gestures. This storytelling task is recorded on video. The researchers will write this down and note which gestures are being produced. The videos are used to calculate two variables: the ratio of the number of gestures to words, and the ratio of gestures that are replacements of speech to all gestures (both speech replacement and complementary to speech). These variables are related to the results of the cognitive tests.

Task3. The researcher starts a 1-on-1 interview (10 minutes) with the participant. This conversation partly proceeds according to a semi-structured script: a few questions have been drawn up in advance. Each question or comment contains two content words that make a gesture possible. During half of the scripted questions, the researcher will not use any gesture. During the other half, the researcher will produce the two gestures. As with a semi-structured interview, the researcher ensures a natural conversation. The conversations are recorded on video. The researcher transcribes the interviews and indicates whether the participant takes over the gestures of the researcher. Each time a script gesture is presented, the examiner indicates whether the participant has responded by applying the spoken word and / or the gesture. By involving the cognitive test results, it can be analyzed whether people with higher semantic processing and higher visual-spatial skills take over from others more often than those with weaker semantic processing skills and weaker visual-spatial skills.
The objective is to demonstrate that omitting ureteral stent placement in robotic intracorporeal urinary diversion does not lead to increased risk of perioperative complications, namely ureteral strictures or anastomotic leaks. We retrospectively reviewed the records of 68 consecutive patients who underwent robotic radical cystectomy with ileal conduit creation or orthotopic neobladder by a single surgeon between January 2020 and September 2023. Chronologically, the first cohort of patients had ureteral stents placed to bridge the ureteroenteric anastomosis, and in the second cohort, stenting was omitted. Cohort 1 consisted of 28 patients with surgeries performed between January 2020 and April 2021, while cohort 2 had 40 patients who underwent surgery from April 2021 to September 2023. The cohorts were well matched with regard to patient age, gender, ASA score and rate of neoadjuvant chemotherapy. The choice of urinary diversion was left to surgeon and patient preference, and there was no significant difference in the proportion of ileal conduits versus orthotopic neobladders within each cohort. Estimated blood loss, total operative time, inpatient length of stay and pathologic T and N staging did not statistically differ between the cohorts. Overall, there was no difference in the rates of postoperative ileus, ureteral stricture, anastomotic leak, infectious complications, and 30-day readmission rates between the groups. Tubeless ureteroenteric anastomosis in patients undergoing robotic radical cystectomy with intracorporeal diversion does not appear to increase the risk of anastomotic strictures or postoperative complications. Further prospective evaluation is warranted.
1. A method of reducing mortality and morbidity after myocardial infraction, comprising administering to a patient in need thereof, a compound selected from the group consisting of GLP-1, GLP-1 analogs, GLP-1 derivatives and pharmaceutically-acceptable salts thereof, at a dose effective to normalize blood glucose. 2. The method of claim 1, wherein the compound is administered intravenously. 3. The method of claim 2, wherein the compound is administered subcutaneously. 4. The method of claim 3 wherein the rate of administration of the compound is between 0.25 and 6 pmol/kg/min. 5. The method of claim 4 wherein the rate of administration of the compound is between 0.5 and 2.4 pmol/kg/min. 6. The method of claim 4 wherein said rate is between about 0.5 and about 1.2 pmol/kg/min. 7. The method of claim 1 wherein the compound is administered intravenously intravenously and also administered by another parenteral route. 8. The method of claim 1 wherein the other parenteral route is the subcutaneous route. 9. The method of claim 1 wherein the compound administered is GLP(7-36) amide, or a pharmaceutically-acceptable salt thereof. 10. A method of reducing mortality and morbidity after myocardial infraction, comprising administering a compound that exerts insulinotropic activity by interacting with the same receptor or receptors, with which GLP-1 interacts in exerting their insulinotropic activity. 11. A method of reducing mortality and morbidity after myocardial infraction, comprising administering a compound that enhances insulin sensitivity by interacting with the same receptor or receptors, with which GLP-1 interacts to enhance insulin sensitivity.
The study medication (either placebo or Duloxetine) will be continued throughout the duration of hospitalization. The balance of the remaining pills will be provided to the patient as a discharge prescription to allow for 10 days total treatment.
BACKGROUND: Basal cell hyperplasia is commonly observed in nasal polyp epithelium of eosinophilic chronic rhinosinusitis (eCRS). We examined the function and mechanisms of basal cell hyperplasia in the pathophysiology of eCRS.
METHODS: We found that normal human bronchial epithelial (NHBE) cells obtained basal cell characteristics when cultured with PneumaCult™-Ex Plus Medium. Most of the cells passaged three times expressed basal cell surface markers CD49f and CD271 by flow cytometry, and basal cell nuclear marker p63 by immunohistochemical staining. We named these NHBE cells with basal cell characteristics cultured Basal-like cells (cBC), and NHBE cells cultured with BEGM™ cultured Epithelial cells (cEC). The characteristics of cBC and cEC were examined and compared by RNA sequencing, RT-PCR, ELISA, and cell proliferation studies.
RESULTS: RNA sequencing revealed that cBC showed higher gene expression of thymic stromal lymphopoietin (TSLP), IL-8, TLR3, and TLR4, and lower expression of PAR-2 compared with cEC. The mRNA expression of TSLP, IL-8, TLR3, and TLR4 was significantly increased in cBC, and that of PAR-2 was significantly increased in cEC by RT-PCR. Poly(I:C)-induced TSLP production and LPS-induced IL-8 production were significantly increased in cBC. IL-4 and IL-13 stimulated the proliferation of cBC. Finally, the frequency of p63-positive basal cells was increased in nasal polyp epithelium of eCRS, and Ki67-positive proliferating cells were increased in p63-positive basal cells.
CONCLUSIONS: Type 2 cytokines IL-4 and IL-13 induce basal cell hyperplasia, and basal cells exacerbate type 2 inflammation by producing TSLP in nasal polyp of eCRS.
The subject will adopt a semi-seated position on a bed while the mirror board is positioned between the legs perpendicular to the subject's midline. The paretic leg will be positioned behind the mirror, with the intact leg facing the reflective surface. All subjects will be reminded to focus on the image in the mirror during MT training. All subjects will receive concurrent TENS stimulation over the common peroneal nerve while practising bilateral lower limb exercises. After 15 minutes of priming with TENS + MT, all subjects will perform 60 minutes of lower limb task-oriented training.
This blinded randomized-controlled trial will be performed through the Division of Maternal Fetal Medicine at Beth Israel Deaconess Medical Center. We will offer enrollment to any pregnant woman at gestational weeks 14+0/7 through 31+6/7 presenting for obstetric ultrasound where cervical assessment and/or placental location determination is indicated. Patient positioning and image acquisition will follow a standard protocol and will be performed by the co-investigators. Outcome ascertainment will be performed by two co-investigators blinded to participant allocation upon completion of data collection. Demographic and obstetrical outcome data will be collected via review of the medical record. Analysis of primary and secondary outcomes will yield incidence data, and comparisons will be made between groups.
PROBLEM TO BE SOLVED: To obtain an artificial particle in which a useful substance can be entrapped in the internal phase, which has a thin tough external phase and is excellent in the easiness of control of a texture by using a polyaspartate. SOLUTION: An artificial particle having an internal phase and an external phase, wherein the external phase is made of a polyvalent metal salt of a polyaspartic acid, is provided. This particle is obtained by bringing a drop of an aqueous solution of poly(alkali metal aspartate) into contact with a solution of a polyvalent metal salt and thereby forming an external phase containing poly(polyvalent metal aspartate) at the interface between both solutions. It is desirable that the concentration of the aqueous solution containing poly(alkali metal aspartate) is about 10wt.% or above. It is desirable that the concentration of the solution of the polyvalent metal salt is about 10wt.% or above. The alkali metal of the poly(alkali metal aspartate) is desirably sodium. An example of the polyvalent metal salt solution is an aqueous calcium chloride solution.
Myelosuppression (including anemia, leukopenia, pancytopenia, and thrombocytopenia) has been reported during postmarketing use of ZYVOX (see WARNINGS). Peripheral neuropathy, and optic neuropathy sometimes progressing to loss of vision, have been reported in patients treated with ZYVOX. Lactic acidosis has been reported with the use of ZYVOX (see PRECAUTIONS). Although these reports have primarily been in patients treated for longer than the maximum recommended duration of 28 days, these events have also been reported in patients receiving shorter courses of therapy. Serotonin syndrome has been reported in patients receiving concomitant serotonergic agents, including antidepressants such as selective serotonin reuptake inhibitors (SSRIs) and ZYVOX (see PRECAUTIONS). Convulsions have been reported with the use of ZYVOX (see PRECAUTIONS). Anaphylaxis, angioedema, and bullous skin disorders such as those described as Stevens Johnson syndrome have been reported. Superficial tooth discoloration and tongue discoloration have been reported with the use of linezolid. The tooth discoloration was removable with professional dental cleaning (manual descaling) in cases with known outcome. These events have been chosen for inclusion due to either their seriousness, frequency of reporting, possible causal connection to ZYVOX, or a combination of these factors. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made and causal relationship cannot be precisely established.
Novel optical imaging techniques such as confocal laser endomicroscopy (CLE) have emerged in recent years as techniques that actually enable in vivo real-time microscopic analysis of malignancies of the GI-tract and lung cancer. Through recent advances the probe became small enough to fit through a biopsy needle and can be used during CT-guided and endosonographic guided biopsies (EUS-FNA). Patients with intra-thoracic malignancies often require invasive procedures such as bronchoscopy, thoracoscopy, mediastinoscopy, transthoracic needle aspiration or surgical exploration to obtain a diagnosis. Intra thoracic malignancies encompass lung cancers, thymomas and malignant pleural mesothelioma. These tumors often present with pleural thickening, unilateral pleural effusion, mediastinal enlargement or a peripheral located mass in the lungs. Tissue collection of the suspected pleural thickening is required to assess a diagnosis and differentiate between the tumor types, to classify and to stage in a proper manner. To date, the different biopsy methods, such as CT-guided pleural biopsy, mediastinal biopsy, endosonography and thoracoscopy have their limitations in diagnosing these malignancies. Sampling errors frequently occur resulting in the common histological finding of 'non-specific pleuritic/fibrosis', which presents a great uncertainty for clinicians and patients. Novel microscopic imaging techniques such as CLE are capable of real time imaging on a cellular level. Data of CLE in intra-thoracic malignancies are lacking.
This is a PI-initiated, randomized, unblinded, clinical trial of a technology-based 3 month lifestyle intervention vs. usual care among men with low risk prostate cancer. We will recruit and consent 76 men with prostate cancer at UCSF. The subjects will be asked to complete questionnaires, 7 days accelerometer measurement, body measurements (weight, waist, hip, pulse, blood pressure) and collection of blood specimen at baseline and 3 months. Subjects will be randomized into two arms (Intervention Group and Control Group). The Intervention Group (N=38) will have access to the lifestyle website and an activity monitor (e.g., Fitbit), receive text messages, and be provided with individualized lifestyle recommendations. The Control Group (N=38) will have standard of care and be asked to continue with their usual lifestyle habits. They will receive access to the lifestyle website and be provided with individualized lifestyle recommendations at 3 months.
5.4 Overdose

Signs of overdose may appear suddenly or insidiously. Acute massive overdose may present as coma. Less sudden and/or less severe forms of overdose may present with signs of drowsiness, lightheadedness, dizziness, somnolence, respiratory depression, seizures, rostral progression of hypotonia and loss of consciousness progressing to coma. Should overdose appear likely, the patient should be taken immediately to a hospital for assessment and emptying of the pump reservoir. In cases reported to date, overdose has generally been related to pump malfunction or dosing error [see Overdosage (10)] . 

Extreme caution must be used when filling the implantable pump.

Medtronic SynchroMed® II Programmable Pump should only be refilled through the reservoir refill septum. The Medtronic SynchroMed® II Programmable Pump is also equipped with a catheter access port that allows direct access to the intrathecal catheter. Direct injection into this catheter access port may cause a life-threatening overdose.
Subjects will visit the clinic for a baseline visit and two in-clinic visits. On in-clinic days, subjects will attend the clinic in a fasting state. They will have inserted a Dexcom and Freestyle Libre and a microdialysis catheter. At time = 0, subjects will be administered a glucose rich drink and every 6. minut measurements will be performed. These include a measurement on the IMD, microdialysate, FreeStyle Libre and Dexcom readings. Every 18. minut a venous blood sample will be included and every 36. minut a capillary blood sample will be collected. This continues until time = 180 minutes.
Diel fluctuations of oxygen levels characterize cyclic hypoxia and pose a significant challenge to wild fish populations. Although recent research has been conducted on the effects of hypoxia and reoxygenation, mechanisms by which fish acclimatize to cyclic hypoxia remain unclear, especially in hypoxia-sensitive species. We hypothesized that acclimation to cyclic hypoxia requires a downregulation of aerobic metabolic rate and an upregulation of mitochondrial respiratory capacities to mitigate constraints on aerobic metabolism and the elevated risk of oxidative stress upon reoxygenation. We exposed Arctic char (Salvelinus alpinus) to 10 days of cyclic hypoxia and measured their metabolic rate and mitochondrial physiology to determine how they cope with fluctuating oxygen concentrations. We measured oxygen consumption as a proxy of metabolic rate and observed that Arctic char defend their standard metabolic rate but decrease their routine metabolic rate during hypoxic phases, presumably through the repression of spontaneous swimming activities. At the mitochondrial level, acute cyclic hypoxia increases oxygen consumption without ADP (CI-LEAK) in the liver and heart. Respiration in the presence of ADP (OXPHOS) temporarily increases in the liver and decreases in the heart. Cytochrome c oxidase oxygen affinity also increases at day 3 in the liver. However, no change occurs in the brain, which is likely primarily preserved through preferential perfusion (albeit not measured in this study). Finally, in vivo measurements of reactive oxygen species revealed the absence of an oxidative burst in mitochondria in the cyclic hypoxia group. Our study shows that Arctic char acclimatize to cyclic hypoxia through organ-specific mitochondrial adjustments.
A purified membrane-bound ceramide-activated protein kinase having an apparent molecular weight of about 97 kD as determined by SDS polyacrylamide gel electrophoresis is provided. This protein kinase specifically phosphorylates the threonine residue in a Pro-Leu-Thr-Pro containing polypeptide. A method of determining whether an agent is capable of specifically inhibiting the phosphorylation activity of the ceramide-activated protein kinase is also provided. A method of determining whether an agent is capable of specifically stimulating the phosphorylation activity of the ceramide-activated protein kinase is further provided. A method of treating a subject having an inflammatory disorder is further provided. A method of treating a human subject infected with HIV so as to reduce the proliferation of HIV in the human subject is further provided. Finally, a method of treating a subject having a disorder associated with poor stem cell growth is provided. The figure shows the effect of phospholipases on the ceramide-activate protein kinase catalyzed phosphorylation in the presence of TNF-.alpha..
The volunteers that have been randomly assigned to this arm of the study will receive one oral capsule per day of the placebo product (Biopolis SL) during the 1 month intervention period. The product contains maltodextrin and sugar.
Varenicline is not recommended for use in pediatric patients 16 years of age or younger because its efficacy in this population was not demonstrated.

Single and multiple-dose pharmacokinetics of varenicline have been investigated in pediatric patients aged 12 to 17 years old (inclusive) and were approximately dose-proportional over the 0.5 mg to 2 mg daily dose range studied. Steady-state systemic exposure in adolescent patients of bodyweight >55 kg, as assessed by AUC (0-24), was comparable to that noted for the same doses in the adult population. When 0.5 mg BID was given, steady-state daily exposure of varenicline was, on average, higher (by approximately 40%) in adolescent patients with bodyweight ≤ 55 kg compared to that noted in the adult population.

Additional information describing a clinical study in which efficacy was not demonstrated in pediatric patients is approved for Pfizer Inc.’s Chantix (varenicline) tablets. However, due to Pfizer Inc.’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.
Cancer and cardiovascular disease are the leading causes of death for Canadian women. One in eight Canadian women will receive the life-changing diagnosis of breast cancer (BC) in their lifetime, with 1 in 34 dying from the disease. Although doxorubicin (DOX) and trastuzumab (TRZ) have significantly improved survival in women diagnosed with human epidermal growth factor receptor 2 (HER2)-positive BC, approximately one in four women who receive this treatment are at risk of developing chemotherapy-induced cardiotoxicity. Cardiotoxicity is defined as a decline in left ventricular ejection fraction (LVEF) of >10% to an absolute value of <53%. Current guidelines recommend the serial monitoring of LVEF in this patient population using non-invasive cardiac imaging modalities including transthoracic echocardiography or multi-gated acquisition scan; however, this will only allow for the detection of established cardiotoxicity. Recent studies have demonstrated that a reduction in global longitudinal strain by speckle tracking echocardiography can identify pre-clinical systolic dysfunction prior to a decline in overall LVEF. Implementation of early detection techniques would allow for the prompt initiation of cardioprotective strategies. In addition to the early detection of chemotherapy-mediated cardiotoxicity, the prophylactic use of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, β-blockers, statins, exercise, and nutraceutical therapies have been studied in the setting of cardio-oncology.
Phase II:Participants will be randomized to group A and B. Group A:receive a dose of Q-1802 at Cycle 1 Day 1 followed by a same dose in subsequent cycles every 2 weeks. Additionally, participants will receive XELOX (capecitabine/oxaliplatin) treatment until investigator confirmed disease progression or a total of 8 treatments (each cycle is defined as approximately 21 days). Oxaliplatin is administered on day 1 of each cycle, whereas capecitabine is taken twice daily on days 1 through 14. After a maximum of 8 treatments of Oxaplatin, subjects may continue to receive Q-1802 a every 2 weeks each cycle and capecitabine every 3 weeks at the investigator's discretion until the subject meets study treatment discontinuation criteria. Group B:Participants will receive XELOX (capecitabine/oxaliplatin) treatment alone until a total of 8 treatments (each cycle is defined as approximately 21 days). subjects may continue to receive capecitabine every 3 weeks at the investigator's discretion.